Wolff-Parkinson White syndrome (WPW) AVRT ✅

📊 WPW Mortality Risk Factors

💡 Note: Symptomatic patients or those with high-risk features should be referred for electrophysiology study and catheter ablation. 📚 References: Pappone C, et al. Circulation 2003;108:2286–2291; Chen SA, et al. J Cardiovasc Electrophysiol 2001;12:1282–1291; ESC Guidelines, Eur Heart J 2019;40:1573–1601.

🏥 Definitive Management of WPW Syndrome

• 🎯 Radio-frequency catheter ablation (RFCA)
  • First-line treatment for patients with recurrent symptomatic SVT or high-risk accessory pathways (short refractory period, prior syncope, or documented pre-excited AF).
  • Success rates are high: ~95–98% for single accessory pathway ablation.
  • Reduces risk of sudden cardiac death by eliminating pre-excitation and preventing rapid conduction during AF.
  • Procedure involves mapping the accessory pathway and delivering RF energy to interrupt conduction.
  • ⚠️ Complications are rare but may include:
    • AV block (~1%) → may require permanent pacemaker
    • Vascular injury at access site (femoral vein/artery)
    • Pericardial effusion or tamponade (<1%)
    • Arrhythmia recurrence (~3–5%) requiring repeat ablation
  • Pre-procedural considerations: anticoagulation if AF present, review antiarrhythmic drugs, baseline ECG and echocardiography.
  • Post-procedure: monitor for arrhythmia recurrence, ECG follow-up, advise patients regarding symptom recognition.
• 💊 Medical Therapy (Adjunct / Bridging)
  • For patients awaiting ablation, or those not suitable for procedure. Options include:
    • Class Ic antiarrhythmics (Flecainide, Propafenone) for AVRT prevention in structurally normal hearts
    • Amiodarone if other antiarrhythmics contraindicated or in patients with structural heart disease
  • Not first-line due to lower efficacy and potential long-term toxicity.
• 🩺 Indications for Catheter Ablation
  • Symptomatic WPW with recurrent SVT.
  • High-risk features: prior syncope, short refractory pathway, history of pre-excited AF.
  • Occupational risk: pilots, athletes, military personnel.
  • Asymptomatic patients may be considered if EPS demonstrates high-risk pathway characteristics.
• 🧾 Alternative / Surgical Approaches
  • Rarely, surgical ablation is used if RF ablation fails or anatomy is unsuitable.
  • Maze procedure during concomitant cardiac surgery may incidentally eliminate accessory pathways.
• 📋 Follow-up
  • Post-ablation ECG to confirm loss of pre-excitation.
  • Holter monitoring in selected patients to detect recurrent arrhythmias.
  • Long-term prognosis excellent: low recurrence and normalized risk of SCD.
  • Patient education: recognize palpitations, syncope, or irregular pulse as triggers for prompt evaluation.

🩺 Case Examples

Case 1 – Stable SVT in WPW: 24yo man, palpitations, HR 180 bpm, ECG shows narrow-complex tachycardia, previous delta wave. Management: 💊 Procainamide or flecainide; consider ablation. ❌ Avoid AV nodal blockers (adenosine/verapamil/beta-blockers/digoxin in pre-excited AF).

Case 2 – Pre-excited AF: 32yo woman, HR >200 bpm, irregular wide QRS, stable. Management: 💊 IV Procainamide or Ibutilide; DC cardioversion if unstable; EP referral for ablation. ❌ Avoid AV nodal blockers.

Case 3 – Incidental WPW: 19yo asymptomatic, ECG shows delta wave. Management: 🩺 No acute treatment; counsel; risk stratify with EP study; ablation if high-risk occupation. ❌ Avoid ignoring risk in athletes/pilots.

⚠️ Safety Tip: Always distinguish **pre-excited AF from regular SVT** – AV nodal blockers in pre-excited AF can trigger ventricular fibrillation.

📚 References

• Brugada J, et al. ESC Guidelines for the management of supraventricular tachycardia. Eur Heart J. 2019;40:1573–1601.
• Pappone C, et al. Radiofrequency catheter ablation in WPW syndrome: long-term follow-up. Circulation. 2003;108:2286–2291.
• Chen SA, et al. Electrophysiologic characteristics and management of WPW. J Cardiovasc Electrophysiol. 2001;12:1282–1291.